Data are available from the University of Liverpool open access repository: [10.17638/datacat.liverpool.ac.uk/302](https://doi.org/10.17638/datacat.liverpool.ac.uk/302)

Introduction {#sec001}
============

Brucellosis is a zoonotic disease with a global distribution that can cause severe illness in people and important economic losses in livestock \[[@pntd.0005508.ref001]--[@pntd.0005508.ref004]\]. *Brucella abortus* and *B*. *melitensis* are the most important zoonotic pathogens, and both species are likely to be endemic in cattle and small ruminants in Kenya \[[@pntd.0005508.ref005]--[@pntd.0005508.ref007]\].

In humans, brucellosis is a debilitating disease that can cause a wide range of symptoms including fever, arthralgia, myalgia and fatigue \[[@pntd.0005508.ref008]--[@pntd.0005508.ref010]\]. Development of focal (e.g. joint, pulmonary, gastrointestinal, hepatobiliary, genitourinary and neurological) complications is common and influenced by the length of time before diagnosis and initiation of treatment \[[@pntd.0005508.ref011],[@pntd.0005508.ref012]\]. Treatment of human disease requires long courses of combined antibiotics and whilst rates of relapse are low with the best regimes \[[@pntd.0005508.ref013]\], compliance in resource-limited countries is often difficult to achieve. Brucellosis can therefore be a considerable economic burden on affected individuals, both in terms of the cost of therapy and days of potential work lost \[[@pntd.0005508.ref014],[@pntd.0005508.ref015]\]. Whilst animal contact is a major risk factor for human infection, *Brucella* spp. are excreted in milk and may be present in the offal and meat of infected animals \[[@pntd.0005508.ref016]\]. Hence, individuals living in both livestock and non-livestock keeping households may be at risk in areas in which *Brucella* spp. are endemic in animals. There is no human vaccine, and prevention of infection relies on reducing people's exposure to infected animals and animal products \[[@pntd.0005508.ref016]\].

Little is known about the prevalence of human brucellosis in sub-Saharan Africa \[[@pntd.0005508.ref001],[@pntd.0005508.ref017]\]. The disease can mimic a variety of acute febrile illnesses, and laboratory tests are essential for diagnosis. Identifying cases presents a particular challenge in settings with limited laboratory capacity and where better-known causes of fever, such as malaria or typhoid, co-occur \[[@pntd.0005508.ref001],[@pntd.0005508.ref017]--[@pntd.0005508.ref021]\]. It is generally considered that human brucellosis is under-diagnosed in many of the areas in which it is endemic in livestock \[[@pntd.0005508.ref009],[@pntd.0005508.ref022],[@pntd.0005508.ref023]\].

Culture of clinical specimens has 100% specificity, but often poor sensitivity, particularly in chronic cases, and also requires the availability of appropriate facilities \[[@pntd.0005508.ref024]\]. Serological tests are therefore the mainstay of laboratory diagnosis in the majority of endemic areas. Serum agglutination assays using whole smooth *Brucella* cell suspensions as antigens are the most commonly used test and are available in a variety of formats. These include the rapid slide *Brucella* agglutination test performed with plain serum at neutral pH and the buffered plate agglutination tests, a family of rapid tests that use *B*. *abortus* suspensions in lactate buffer at low pH. The Rose Bengal Test (RBT) is the most widely used of the buffered plate agglutination tests \[[@pntd.0005508.ref025]\]. While these rapid tests may be used to provide a semi-quantitative assessment of antibody titre through serial dilutions, the standard tube agglutination test (SAT), performed with serum dilutions in tubes or microplates at neutral pH using saline as the diluent, enables more accurate assessment of antibody levels \[[@pntd.0005508.ref024]\]. Infection with *Brucella* can result in the production of antibodies that do not agglutinate at neutral pH, which steadily increase and replace agglutinating antibodies over the course of the infection \[[@pntd.0005508.ref011],[@pntd.0005508.ref025]--[@pntd.0005508.ref027]\]. Thus, the SAT is usually complemented with the *Brucella* Coombs test \[[@pntd.0005508.ref028]\], an IgG and IgA anti-immunoglobulin assay \[[@pntd.0005508.ref011],[@pntd.0005508.ref024],[@pntd.0005508.ref025]\]. All of these tests detect antibodies to the *Brucella* smooth lipopolysaccharide \[[@pntd.0005508.ref024]\], and the purified antigen is also used in a variety of non-agglutination based tests, including the lateral flow immunochromatographic assay (LFA) \[[@pntd.0005508.ref029],[@pntd.0005508.ref030]\]. The sensitivity and specificity of serological testing for brucellosis varies depending upon the characteristics of the test and the antigenic suspensions used, as well as the stage of infection \[[@pntd.0005508.ref024]--[@pntd.0005508.ref027]\]. Reduced specificity can result from the persistence of anti-lipopolysaccharide antibody titres in a proportion of recovered patients as well as infections by cross-reacting bacteria \[[@pntd.0005508.ref026],[@pntd.0005508.ref027],[@pntd.0005508.ref031]--[@pntd.0005508.ref033]\].

The serological test currently used for the laboratory diagnosis of human brucellosis in government health facilities in Kenya and, to our knowledge, throughout Tanzania and Uganda, is a variant of the rapid slide *Brucella* agglutination test. There are several commercial kits currently available in East Africa, comprising separate *'melitensis'* and *'abortus'* antigens, marketed as part of a \"febrile antigen test" kit. Despite their widespread use in East Africa, very little has been reported regarding the diagnostic accuracy of these febrile antigen *Brucella* agglutination tests (FBAT) or their predictive value in brucellosis endemic areas. Clearly, filling this information gap has important implications for the clinical application of this test. Furthermore, a recent review highlighted the paucity of data available to estimate global human brucellosis burden, and identified the strengthening of public health systems as an important mechanism to improve the quality of data captured through routine reporting \[[@pntd.0005508.ref034]\]. A major consideration in interpreting the data generated by public health systems is the performance of tests used to diagnose brucellosis in endemic areas.

The aim of this study was to assess the performance of the FBAT as currently used in health facilities in Kenya. We conducted a serological and questionnaire-based survey of individuals presenting to health facilities in western Kenya with symptoms compatible with brucellosis. The performance of the FBAT was compared with that of a range of serological assays with well-established diagnostic performance. To provide epidemiological evidence to support test performance, logistic regression was used to explore predictors of FBAT seropositivity.

Methods {#sec002}
=======

Ethics statement {#sec003}
----------------

Ethical approval for the study was granted by the Kenya Medical Research Institute (KEMRI) ethical review board (SCC1701). All participants provided written informed consent; minors between 5 and 17 signed an assent document and their guardians provided consent.

Study area {#sec004}
----------

The study was conducted in Busia county which has a total area of 1637 km^2^ and a population of 786,365 people (Open Kenya). Two health facilities were selected for this study. These were Busia County Referral Hospital (BCH) and a private clinic at the Kenya Medical Research Institute (KEMRI) field station at Alupe. Livestock production in the County is characterised by a predominantly small-scale, mixed crop and livestock system \[[@pntd.0005508.ref035]\].

Patient selection and sampling {#sec005}
------------------------------

Sampling took place on weekdays from June to December 2012. A separate focus of the study was to use epidemiological tools to identify the source of infection in suspect brucellosis cases, with sampling effort intended to maximise the number of identified cases within the study period. Patients attending the outpatient clinic of BCH and the KEMRI clinic were recruited into the study by non-study health centre clinicians. The criterion for inclusion was clinical suspicion of brucellosis, including exposure history and compatible symptoms (see [Table 1](#pntd.0005508.t001){ref-type="table"}). We therefore aimed to include those patients who would normally present for laboratory-based brucellosis testing within either health facility. Exclusion criteria were patients less than 5 years of age, minors (5--17 years) not accompanied by a guardian, patients presenting with severe illness requiring hospitalisation, and those patients with an already established diagnosis explaining illness. Patients typically pay for brucellosis diagnostics in government facilities in Kenya (1.50--3.00 USD), but testing was provided free of charge to all participants enrolled in this study.

10.1371/journal.pntd.0005508.t001

###### Presenting symptoms and exposure characteristics of study participants.

![](pntd.0005508.t001){#pntd.0005508.t001g}

  Presenting signs      \% (95% CI)         Exposures[\*](#t001fn001){ref-type="table-fn"}   \% (95% CI)
  --------------------- ------------------- ------------------------------------------------ -------------------
  Malaise               88.5 (85.8--90.7)   Male gender                                      31.3 (27.9--34.9)
  Headache              79.2 (76.0--82.1)   Travel outside home county                       20.4 (17.5--23.6)
  Fever                 64.6 (60.9--68.1)   Previous brucellosis diagnosis                   11.6 (9.3--14.2)
  Abdominal pain        60.5 (56.7--64.1)   Know someone with similar symptoms               7.3 (5.5--9.5)
  Anorexia              54.3 (50.6--58.1)   Know someone with brucellosis diagnosis          20.3 (17.5--23.5)
  Joint pain            51.1 (47.3--54.8)   High risk milk consumption                       7.6 (5.8--9.9)
  Back pain             43.2 (39.6--47.0)   High risk yoghurt consumption                    15.1 (12.5--18.1)
  Sweats                42.2 (38.6--46.0)   High risk meat consumption                       2.7 (1.6--4.3)
  Chills                37.6 (34.0--41.3)   Blood consumption                                4.1 (2.8--5.9)
  Chest pain            34.4 (30.9--38.1)   Keep cattle at home                              47.5 (43.7--51.3)
  Muscle aches          34.2 (30.7--37.8)   Keep sheep or goats at home                      31.5 (28.1--35.1)
  Cough                 27.3 (24.1--30.8)   Keep pigs at home                                20.6 (17.7--23.8)
  Constipation          25.3 (22.2--28.7)   Cattle born in compound                          13.6 (11.2--16.4)
  Neck pain             17.2 (14.5--20.3)   Sheep/goats born in compound                     7.0 (5.3--9.2)
  Diarrhoea             12.4 (10.1--15.1)   Direct contact with animal birth products        2.7 (1.6--4.3)
  Vomiting              11.1 (8.9--13.7)    Abortion in compound                             1.9 (1.0--3.2)
  Sore throat           9.2 (7.3--11.7)     Involvement in animal slaughter                  1.0 (0.44--2.1)
  Breathlessness        6.8 (5.1--9.0)                                                       
  Weight loss           3.2 (2.0--4.8)      Any high risk food consumption                   21.4 (18.4--24.6)
  Joint swelling        3.0 (1.9--4.6)      Any high risk animal contact                     5.5 (3.9--7.6)
  Rash                  2.3 (1.4--3.8)      Any high risk activity (food or animal)          25.8 (22.6--29.4)
  Orchitis (in males)   0.9 (0.2--3.5)                                                       

\* In the 180 days prior to onset of clinical symptoms.

A study technician collected 6 ml of blood from study participants into a plain tube. Clotted blood was spun at 3000 rpm for 5 to 10 minutes and serum extracted.

Patient interviews {#sec006}
------------------

Each consenting or assenting participant underwent a questionnaire interview with a study clinician who collected information on clinical history, presenting clinical symptoms, and health seeking behaviour. On the basis of a maximum expected brucellosis incubation period of 6 months \[[@pntd.0005508.ref036]\], participants were given a structured questionnaire in which they were asked to recall high-risk exposures (i.e. to food products or livestock) in the 180 days prior to the onset of symptoms.

Serological assays in hospital {#sec007}
------------------------------

Serum was used to perform the FBAT and RBT at BCH and the KEMRI clinic. Antigens for the FBAT used in these settings were manufactured by Fortress diagnostics, UK ([http://www.fortressdiagnostics.com](http://www.fortressdiagnostics.com/), \"Febrile Antigen Kit\") and purchased locally. Standard hospital operating procedures were used for the FBAT. These were the same in both health centres and involved mixing a 50μl drop of serum with a drop (approximately 50μl) of '*abortus*' antigen and drop of '*melitensis*' antigen on a dedicated agglutination slide. Serum and antigen solution were rotated on a mechanical rotator for 2 minutes. As per standard procedures in both health facilities, tests were reported as 'reactive' if any evidence of agglutination was observed on naked eye examination. While the study health centres did not routinely measure antibody titres in reactive samples, these were semi-quantitatively assessed as part of this study using a serial dilution approach as described by the manufacturers. For this, 80, 40, 20, 10 and 5 μl drops of serum were placed on agglutination tiles and a 50 μl drop of reagent was added to each, followed by mixing and rotation for 2 minutes. Agglutination in the first, second, third, fourth or fifth well was considered suggestive of a 1:20, 1:40, 1:80, 1:160 or 1:320 titre, respectively.

The RBT performed in each health centre followed standard procedures \[[@pntd.0005508.ref025]\] and involved mixing 25μl of serum with 25μl of antigen on a white glossy ceramic tile with a wooden toothpick and rotation on a mechanical rotator for 4 minutes. The antigen, produced at the University of Navarra, was a suspension of fully smooth *B*. *abortus* 1119 standardized according to internationally established guidelines \[[@pntd.0005508.ref037]\] and controlled for quality using a panel of brucellosis positive and negative serum samples \[[@pntd.0005508.ref038]\]. Samples were confirmed as reactive if any perceptible agglutination, including the formation of a ring around the sample \[[@pntd.0005508.ref025]\], was observed on naked eye examination.

Sera that were reactive using either the RBT or FBAT was subjected to the rapid LFA for the presence of IgG and IgM antibodies \[[@pntd.0005508.ref030]\]. This test was marketed by Life Assay (South Africa) and was performed according to the manufacturer's instructions.

Remaining serum was stored at -40°C on the day of collection before being shipped on ice to the University of Navarra, Spain, for confirmatory serological testing. All samples were shipped at the end of the sampling period.

Confirmatory testing {#sec008}
--------------------

At the University of Navarra, samples from the 825 individuals were subjected to a repeat of the RBT. The second RBT was performed by mixing 30μl of serum with 30μl of the aforementioned antigen on a white glossy tile, followed by gentle rotation by hand for 4 minutes, and sera yielding doubtful results rotated for an additional period of 4 minutes. Positive samples were subjected to semi-quantitative titration using the modified version of the test \[[@pntd.0005508.ref025]\]. For this, eight 30μl drops of saline were dispensed on the tile and the first mixed with 30 μl serum. From this, 30μl was transferred to the second drop using a micropipette. This was repeated for each drop to derive dilutions ranging from 1:2 to 1:64. Each drop was tested with an equal volume (30 μl) of the RBT reagent, resulting in a range of final dilutions from 1:2 to 1:128. Positive samples on the FBAT or RBT were also subjected to the SAT and Coombs test. The SAT was performed in a microplate format using a standardised antigenic suspension of *B*. *abortus* 1119--3 as previously described \[[@pntd.0005508.ref039]\] and serum dilutions from 1:20 to 1:2,560. The Coombs test was performed with anti-total human immunoglobulin serum in microplates \[[@pntd.0005508.ref040]\]. A titre ≥1:160 was considered suspicious for the SAT. The Coombs test was considered positive for a titre ≥ 2 times the SAT titre from the same sample \[[@pntd.0005508.ref024]\].

A random selection of FBAT positive samples (n = 24) were retested by technicians at the University of Navarra using the same FBAT test procedure performed in participating health centres, but with a different kit (Febrile Serodiagnostics, Biosystems).

Data analysis {#sec009}
-------------

Multivariable logistic regression was used to assess the relationship between known risk factors for brucellosis and the log odds of seropositivity to the FBAT based on a 1:2 dilution (i.e. equal volumes of serum and each antigen). Risk factors were extracted from the patient interview and were age in years, sex, consumption of high risk milk and yoghurt products, consumption of high risk meat or blood products, direct contact with the birth products of livestock (cattle, sheep, goats or pigs), abortion of livestock in the participant's compound, involvement in livestock slaughter, and knowing someone with a brucellosis diagnosis in the 6 months prior to the onset of symptoms. Food exposures were considered 'high risk' when products were consumed without prior heat treatment, or without adequate heat treatment in the case of blood and meat. The number of variables included in the final model was determined based on the number of FBAT positive results. One variable was selected for every 10 positive cases in order to ensure model complexity did not exceed the available number of degrees of freedom \[[@pntd.0005508.ref041]\]. To meet this criterion, variables for inclusion were either a summarised 'high risk' exposure to any food or livestock, or the component parts (i.e. different food types or different livestock exposure types) where the sample size of FBAT cases allowed. No further model selection was performed. Model fit was assessed using the le Cessie-van Houwelingen normal test. Analysis was conducted using the *rms* package \[[@pntd.0005508.ref041]\] in R, version 3.1.1. (<http://cran.r-project.org/>).

Results {#sec010}
=======

Participant enrolment and demographics {#sec011}
--------------------------------------

A total of 825 individuals attending our study sites for care were recruited into the study, with 691 (84%) coming from BCH and 134 (16%) from the KEMRI clinic. It was possible to conduct the patient survey and collect clinical data from 703 (85%) of these. The presenting symptoms and potential *Brucella* spp. exposure characteristics are summarised in [Table 1](#pntd.0005508.t001){ref-type="table"}. The average age of participants was 37.6 years, with a median of 35 and a range between 5 and 98 years. The mean duration of symptoms was 118 days, but this was skewed by a small number of individuals (n = 8) who reported the duration of current illness as more than 3 years. The median value was 14 days. The majority of individuals (426, 60.6%) reported that this was their first visit to a health care provider for their current illness. Of the remaining 277, 177 (64%) had already visited one health facility without resolution, 61 (22.2%) had visited two, 20 (7.2%) had visited three, 11 (3.9%) had visited four and eight (2.9%) had visited five or more. The median duration of symptoms in those presenting for the first time was seven days compared to 61 days in those who had previously sought health care for their current condition (p\<0.001). High-risk food consumption was reported in 150 (21.4%) participants, and high-risk animal contact (defined as direct contact with animal birth products, animal abortion in the participant's home compound or involvement in livestock slaughter) in 37 (5.5%) individuals ([Table 1](#pntd.0005508.t001){ref-type="table"}).

Brucellosis sero-diagnostics {#sec012}
----------------------------

On the basis of tests performed within study health facilities, a total of 162 out of 825 (19.6%, 95% CI 17.0--22.5) individuals had reactive FBAT tests ([Table 2](#pntd.0005508.t002){ref-type="table"}). At BCH, 147 (21.3%, 95% CI 18.3--24.6) FBAT tests were reactive, while at the KEMRI clinic, 15 (11.2%, 95% CI 6.6--18.0)) were reactive. When the test was performed on serum dilutions, fifteen out of 162 (1.8%, 95% CI 1.1--3.1)) were seropositive at titres ≥1:160 while 2 (0.2%, 95% CI 0.04--0.9) were seropositive at titres ≥1:320, representing 9.3% and 1.2% of all FBAT positive tests, respectively. Of all 162 FBAT positives, 104 (62.4%) were reactive to both the '*abortus*' and '*melitensis*' antigen, while 44 (27.2%) were reactive to the '*abortus'* antigen only and 14 (8.6%) reactive to the '*melitensis'* antigen only. Of the 15 FBAT tests seropositive at titres ≥1:160, all but 1 were reactive to both *abortus* and *melitensis* antigen, while both of the FBAT tests seropositive at titres ≥1:320 were reactive to both antigens. Individuals with FBAT titres ≥1:160 were more likely to be reactive to both antigens compared to individuals with FBAT titres \<1:160 (OR = 8.9, 95% CI 1.3--387, p = 0.01).

10.1371/journal.pntd.0005508.t002

###### Comparison of FBAT, RBT, SAT Coombs IgG and LFA in the 825 sera.

![](pntd.0005508.t002){#pntd.0005508.t002g}

  FBAT (n)                                                           Number of sera                                                                                                                                                             
  ---------------- ------------------------------------------------- ---------------- --- ------------------------------------------------- ------------------------------------------------- ------------------------------------------------- -------------------------------------------------
  Positive (162)   RBT+ [^**b**^](#t002fn002){ref-type="table-fn"}   8                0   1 [^**c**^](#t002fn003){ref-type="table-fn"}      2                                                 2 [^e^](#t002fn005){ref-type="table-fn"}          0 [^e^](#t002fn005){ref-type="table-fn"}
                   RBT-                                              154              0   0                                                 1                                                 3 [^e^](#t002fn005){ref-type="table-fn"}          0 [^e^](#t002fn005){ref-type="table-fn"}
  Negative (663)   RBT+                                              0                0   0                                                 0                                                 n.d. [^**d**^](#t002fn004){ref-type="table-fn"}   n.d. [^**d**^](#t002fn004){ref-type="table-fn"}
                   RBT-                                              663              0   n.d. [^**d**^](#t002fn004){ref-type="table-fn"}   n.d. [^**d**^](#t002fn004){ref-type="table-fn"}   n.d. [^**d**^](#t002fn004){ref-type="table-fn"}   n.d. [^**d**^](#t002fn004){ref-type="table-fn"}
  Total                                                              825              0   1                                                 3                                                 5                                                 0

^a^ A titre ≥ 2 times the SAT titre was considered as positive.

^b^ RBT in health facilities in Kenya and /or at the University of Navarra (see [Table 3](#pntd.0005508.t003){ref-type="table"}).

^c^ This serum developed an atypical agglutination and only at a 1:80--1:160 titre.

^d^ n.d., not done.

^e^ Out of 148 positives tested.

Eight out of all 825 individuals (1.0%, 95% CI 0.4--2.0) were found to be positive using the RBT ([Table 2](#pntd.0005508.t002){ref-type="table"}). Of these, 6 were positive in the RBT performed in the study health facilities and four had titres ≥1:160 and 1 had a titre ≥1:320 when FBAT was performed on serum dilution. Similarly, 6 individuals were weakly positive on the basis of the repeat RBT at the University of Navarra. There was some discrepancy between the results of the repeat RBT at the University of Navarra and those performed in study health facilities, with 4 out of 6 results matching on both occasions ([Table 3](#pntd.0005508.t003){ref-type="table"}). None of the 8 RBT positive individuals was positive at dilutions equal or higher than 1:4 ([Table 2](#pntd.0005508.t002){ref-type="table"}). Positive sera with FBAT titres ≥ 1:160 were much more likely to be also RBT positive than sera with FBAT titres ≤ 1:160 (OR = 22.8, 95% CI = 3.8--168.9, p = \<0.001). No FBAT negative sera were RBT positive ([Table 2](#pntd.0005508.t002){ref-type="table"}).

10.1371/journal.pntd.0005508.t003

###### Comparative results for test positive on RBT, LFA, SAT and Coombs.

![](pntd.0005508.t003){#pntd.0005508.t003g}

  Sera   RBT 1[^a^](#t003fn001){ref-type="table-fn"}   RBT 2[^a^](#t003fn001){ref-type="table-fn"}   LFA (IgM)   SAT         Coombs (IgG)   FBAT 'A'   FBAT 'M'
  ------ --------------------------------------------- --------------------------------------------- ----------- ----------- -------------- ---------- ----------
  1      \+                                            \+                                            \-          1:40        1:160          1:160      1:160
  2      \+                                            \+                                            \+          1:20        1:20           1:160      1:160
  3      \+                                            \-                                            \-          1:80--160   1:160          1:320      1:160
  4      \+                                            \+                                            \-          1:20        1:20           1:160      1:80
  5      \+                                            \-                                            \+          \<1:20      \<1:20         1:20       \<1:20
  6      \+                                            \+                                            \-          1:20        1:40           1:40       1:80
  7      \-                                            \+                                            \-          \<1:20      1:640          1:160      1:160
  8      \-                                            \+                                            \-          1:20        1:20           1:80       \<1:20
  9      \-                                            \-                                            \+          nd          nd             1:160      1:80
  10     \-                                            \-                                            \+          nd          nd             1:80       1:160
  11     \-                                            \-                                            \+          nd          nd             1:40       1:20
  12     \-                                            \-                                            \-          1:20        1:320          1:40       1:40

^a^ RBT 1 was performed in health facilities in Kenya; RBT 2 was performed at the University of Navarra.

Out of the 162 FBAT positive sera tested using the SAT at the University of Navarra, 161 were clearly negative with titres below 1:40. The remaining serum (0.62%) showed a 1:80--1:160 titre ([Table 2](#pntd.0005508.t002){ref-type="table"}) which could be considered as suspicious. However, agglutination was atypical and consisted of mucoid filamentous aggregates rather than the typical clumps. This same serum was RBT negative and Coombs negative when tested at the University of Navarra, but was RBT positive when tested in study health facilities. Three (1.4%) sera, all with clearly negative SAT titres (≤ 1:40), were weakly positive using the Coombs test ([Table 3](#pntd.0005508.t003){ref-type="table"}), and of these three, two were weakly RBT positive (Tables [2](#pntd.0005508.t002){ref-type="table"} and [3](#pntd.0005508.t003){ref-type="table"}). A total of 148 of the 162 FBAT reactive sera were tested using the LFA, of which five (3.4%) were also positive using the IgM LFA but negative in the IgG LFA (Tables [2](#pntd.0005508.t002){ref-type="table"} and [3](#pntd.0005508.t003){ref-type="table"}). Three of these five were positive at FBAT titres ≥1:160 ([Table 3](#pntd.0005508.t003){ref-type="table"}).

Of the 24 randomly selected FBAT positive results that were retested at the University of Navarra using a different febrile antigen kit, 23 (96%) were positive.

Risk factors for FBAT seropositivity {#sec013}
------------------------------------

The large number of FBAT seropositives (138 with linked questionnaire data) provided sufficient sample size to allow us to explore the full range of potential predictors of seropositivity. Observed relationships are presented in [Table 4](#pntd.0005508.t004){ref-type="table"}. Knowing someone with a brucellosis diagnosis increased the odds of FBAT seropositivity, as did involvement in animal slaughter. Males were at lower risk of FBAT positivity. The goodness-of-fit test indicated no evidence of any lack of model fit (p = 0.2).

10.1371/journal.pntd.0005508.t004

###### Results of the multivariable analysis using FBAT seropositivity as the outcome.
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  Predictor                                    OR (95% CI)          p-value
  -------------------------------------------- -------------------- ---------
  Age (in years)                               1.01 (0.998--1.02)   0.11
  Male gender                                  0.58 (0.36--0.92)    0.02
  High risk milk consumption                   0.46 (0.17--1.21)    0.12
  High risk yoghurt consumption                1.00 (0.56--1.80)    0.99
  High risk meat consumption                   1.64 (0.55--4.88)    0.38
  High risk blood consumption                  1.21 (0.46--3.18)    0.70
  Contact with livestock birth products        0.93 (0.25--3.45)    0.92
  Contact with abortion materials              1.10 (0.29--4.21)    0.89
  Involvement in animal slaughter              5.02 (1.04--24.26)   0.04
  Knowing someone with brucellosis diagnosis   1.59 (1.01--2.5)     0.04

Discussion {#sec014}
==========

We have demonstrated substantial disagreement between results from the FBAT and results from a range of serological tests that have been repeatedly shown to have high diagnostic accuracy for human brucellosis \[[@pntd.0005508.ref011],[@pntd.0005508.ref024],[@pntd.0005508.ref025],[@pntd.0005508.ref027],[@pntd.0005508.ref030],[@pntd.0005508.ref042]\]. Whilst brucellosis should not be excluded as a possible cause of febrile illness in the population under study, our results suggest it is an uncommon cause, and certainly much rarer than results from the FBAT would suggest. It is important to stress that the small number of positive results obtained using the RBT, SAT-Coombs combination and LFA are not by themselves indicative of active brucellosis. There is no established diagnostic titre for a single SAT, which varies from 1:80 to 320 depending on levels of endemicity \[[@pntd.0005508.ref024]\], and any SAT result should be considered along with the Coomb\'s result. In this study, all but one FBAT positive individual had SAT titres \< 1:160, and only three had weak Coombs titres. In addition, none of the sera were positive on the RBT at dilutions higher than 1:2, which may suggest previous exposure rather than current infection \[[@pntd.0005508.ref025]\]. Five FBAT positive sera were IgM positive in the LFA. The presence of the rheumatoid factor (a group of auto-antibodies that recognize Fc regions of IgG \[[@pntd.0005508.ref043]\]) is a known cause of false positives in this test \[[@pntd.0005508.ref042]\]. Since IgM is readily detected using the SAT \[[@pntd.0005508.ref024]\], this is a possible explanation for the observed discord between LFA and SAT results. In the absence of bacteriological evidence or the availability of convalescent antibody titres, the few positive sera identified using SAT-Coombs, RBT and LFA can therefore only be considered as \"suspicious\" for brucellosis. This fact, combined with the low number of "suspicious" cases identified, limits our ability to derive formal estimates of test performance for the FBAT. However, results from this study strongly suggest that this test generates large numbers of false positives and has poor diagnostic specificity. This interpretation is further supported by the fact that we found no evidence of an association between FBAT seropositivity and most of the anticipated high-risk food or animal exposures. The only exception was involvement with animal slaughter, which has been shown to be a risk factor for human brucellosis in other studies \[[@pntd.0005508.ref044]\].

The poor performance of the FBAT cannot be attributed to the particular kit used in health facilities involved in this study, since a high rate of false positive results were also observed at the University of Navarra with a different kit. Neither health facility involved in this study routinely performed serial dilutions for positive cases and, based on discussion with laboratory managers at other health facilities in western Kenya, the semi-quantitative estimation of antibody titres using the FBAT appears to be rare practice in the region. Our ability to evaluate appropriate cut-offs is limited in this study by the absence of confirmed cases and small number of suspicious cases, but there was evidence of a strong association between RBT positivity and titres ≥1:160 on the FBAT, suggesting the use of a higher cut-off may improve the diagnostic specificity of the test.

The low prevalence of brucellosis in the study population combined with the apparently poor specificity of FBAT suggests considerable overdiagnosis of human brucellosis. An important consideration, however, is that the provision of free brucellosis testing to participants may have contributed to the capture of more patients than would typically be tested for the disease in the study health facilities. It is therefore possible that levels of overdiagnosis indicated by this study are exaggerated. In the period from June 2010 to June 2011, BCH (then named Busia District Hospital) recorded 129 cases of brucellosis, whilst we identified 162 individuals as reactive on the FBAT over an approximately 6 month period between June and December 2012. However, given the small number of suspicious cases we observed over the six months of data collection, the number of cases detected in 2010 and 2011 also point to high levels of overdiagnosis for this disease. Typical treatment for brucellosis in health facilities in the study area is 6 weeks of oral doxycycline combined with either 2 weeks of intramuscular streptomycin or 6 weeks of oral rifampicin. Whilst the clinical management of recruited patients was not recorded as part of this study, treatment is routinely recommended in both health facilities to any individual with a reactive FBAT test. We therefore expect that a substantial proportion of brucellosis treatments in western Kenya are inappropriate. This will result in unnecessary economic costs for patients, and may represent important misuse of antibiotics. This is of particular concern for the selection of resistance to rifampicin, a first line treatment for TB \[[@pntd.0005508.ref045]\].

In 2012, 75,256 brucellosis cases in individuals over five years of age were reported to the Kenya Health Information System ([www.hiskenya.org](http://www.hiskenya.org/)), giving an annual incidence of 230 per 100,000 people \[[@pntd.0005508.ref046]\]. We suspect that the vast majority of these cases were diagnosed on the basis of the FBAT. Whilst brucellosis is very likely to be an important disease in Kenya, particularly amongst pastoral communities \[[@pntd.0005508.ref005],[@pntd.0005508.ref047]\], poor performance of the diagnostic test used to derive surveillance data means there is considerable uncertainty regarding the true burden of human brucellosis in the country.

An internet search revealed that all twelve of the FBAT providers identified include both *B*. *abortus* and *B*. *melitensis* suspensions in their kits. The purpose of this is unclear since it was well established in the first half of the 20^th^ century that suspensions of *B*. *abortus* and *B*. *melitensis* can be exchanged for diagnostic purposes \[[@pntd.0005508.ref018]\]. The target for *Brucella* agglutination tests is the O-polysaccharide of the smooth lipopolysaccharide of the cell surface of smooth *Brucella* species, which has a structure dominated by a highly repeated C epitope common to all smooth brucellae \[[@pntd.0005508.ref048]\] (excluding the recently described *B*. *inopinata* BO1 \[[@pntd.0005508.ref049]\]). Hence, there is no serological test that can distinguish infection with *B*. *abortus* versus *B*. *melitensis* \[[@pntd.0005508.ref011],[@pntd.0005508.ref018],[@pntd.0005508.ref024],[@pntd.0005508.ref048]\]. Despite this, we noted a not unsurprising belief amongst laboratory technicians and clinicians working in both study health facilities that the FBAT, marketed with separate *'abortus'* and *'melitensis'* antigens, can distinguish between infections with these different *Brucella* species. This misconception is likely to be strengthened by the inconsistent results obtained with the *'abortus'* and *'melitensis'* suspensions of FBAT, as illustrated by our work and recently published work from Tanzania \[[@pntd.0005508.ref050]\]. Long and repeated experience \[[@pntd.0005508.ref011],[@pntd.0005508.ref018],[@pntd.0005508.ref024],[@pntd.0005508.ref051]\] shows that the most plausible reasons for these inconsistencies are deficient standardisation of antigen suspensions and poor antigen quality. Smooth brucellae are notorious for their ability to dissociate in vitro, a genetic drift that results in large proportions of rough mutants that lack the O-polysaccharide of the lipopolysaccharide and have profoundly altered cell surface properties \[[@pntd.0005508.ref048]\]. The consequence of this drift is an absence of diagnostically valid epitopes and a strong tendency to autoagglutinate. Such deficient antigenic suspensions are an important cause of false positivity and the likely explanation for the high numbers of false positives obtained with FBAT in this study, as well as for the inconsistency between reactions to '*abortus*' and '*melitensis*' antigens. We consider antigen quality to be a more likely explanation for poor FBAT specificity than cross-reaction with antibodies to other gram negative bacteria, since such cross-reactions are well known to occur for all serological assays that rely on detection of antibodies to the *Brucella* smooth lipopolysaccharide, including RBT, SAT and Coombs \[[@pntd.0005508.ref031]\], and are likely also with the LFA. Whilst the clinical management of infection with *B*. *melitensis or B*. *abortus* is the same, an indirect consequence of the inconsistency between reactions to different FBAT antigens is that results may be misleading with respect to the source of infection, since *B*. *melitensis* is typically associated with small ruminants while *B*. *abortus* is more typically associated with cattle \[[@pntd.0005508.ref016]\].

The catchment area of study health facilities incorporate a mixed farming area with a very high livestock density. Despite this, a substantial proportion of patients presenting for brucellosis diagnostic testing did not report what we considered high risk contacts with livestock or their products over the six months prior to the onset of clinical symptoms. Studies from Tanzania have reported limited awareness of zoonotic disease among health workers \[[@pntd.0005508.ref052]\], including the range of pathways through which *Brucella* species may be transmitted to people \[[@pntd.0005508.ref053]\]. Detailed clinical history taking and the targeting of testing to individuals considered to be at higher risk of brucellosis, is likely to improve the predictive value of serological testing, particularly in low prevalence populations. An important consideration, however, is that whilst we have a broad understanding of the epidemiology of brucellosis in sub-Saharan Africa \[[@pntd.0005508.ref001],[@pntd.0005508.ref017]\], there is generally a lack of information on the specific transmission routes by which people in specific settings acquire their infections. Population-based studies in endemic areas should seek to fill this information gap. Further studies could also seek to derive diagnostic algorithms for human brucellosis that allow for the formalisation of who to test, and who should be considered positive based on a range of criteria, including the results of imperfect serological assays, exposure history and presenting signs \[[@pntd.0005508.ref054],[@pntd.0005508.ref055]\].

Future studies should seek to derive estimates of sensitivity and specificity for the FBAT, including assessment of the value of deriving semi-quantitative estimates of antibody titres. However, given the likely poor specificity we have demonstrated, future work should also examine alternative diagnostic tests that can be used to replace the FBAT in health facilities in western Kenya and the region more widely. The standard RBT is inexpensive and straightforward to perform, follows the same general procedure as the FBAT and thus requires the same basic laboratory equipment and expertise. Several authors have advocated for the routine use of this test in the diagnosis of human brucellosis in health facilities in resource limited settings \[[@pntd.0005508.ref025],[@pntd.0005508.ref056],[@pntd.0005508.ref057]\]. This test showed considerably better agreement with the results of the SAT-Coombs and LFA than the FBAT in this setting, and is likely to represent a better alternative. A potential limitation of the RBT, although one that applies to all rapid agglutination tests, including the FBAT, are inconsistencies between technicians in reading agglutination results \[[@pntd.0005508.ref058]\]. In our study, there was some discrepancy between results of the RBTs performed in Kenya and those performed by different operators in Spain. One of the two weak RBT positives that were missed in Kenya was Coombs positive, whilst one of the two that was missed in Spain was SAT positive. Problems around repeatability are likely to be minimised through the use of a glossy white tile, testing only a limited number of sera each time, adequate training of technicians to recognise all agglutination patterns, and the use of good quality controls \[[@pntd.0005508.ref025]\]. The measurement of RBT titres using serial dilution, and particularly evidence of rising titres on repeat testing, can provide better evidence of infection when combined with clinical presentation and adequate history taking \[[@pntd.0005508.ref025],[@pntd.0005508.ref057]\]. Confirmation of agglutination results with a second test would also contribute to improved diagnostic accuracy. The LFA used in this study provides a simple and inexpensive option, and was found to have good test performance when manufactured by the Royal Tropical Institute, Netherlands \[[@pntd.0005508.ref030]\]. These tests can distinguish between IgM and IgG antibodies, and can therefore also contribute to the clinical assessment of the stage of infection \[[@pntd.0005508.ref059],[@pntd.0005508.ref060]\].

We do not have additional aetiological information for those patients enrolled in this study who appear to have had false positive brucellosis diagnoses, and an important question remains regarding the cause of their illnesses. In addition to HIV, malaria and typhoid, for which many recruited participants were also tested by participating health centres, a wide range of infectious causes of febrile illness are known to be prevalent in the study area. These include *Coxiella burnetii* \[[@pntd.0005508.ref061],[@pntd.0005508.ref062]\], *Leptospira* spp. \[[@pntd.0005508.ref063]\], *Rickettsia* spp. \[[@pntd.0005508.ref064]\], and Chikungunya virus \[[@pntd.0005508.ref065]\]. To our knowledge, neither health facility routinely tested for any of these pathogens at the time of the study, and while rapid tests are available for some, these often have poor diagnostic performance \[[@pntd.0005508.ref066]\] and have not been widely adopted \[[@pntd.0005508.ref067]\]. The demonstration that *Brucella* may be less common than anticipated in this setting therefore increases the diagnostic challenge for clinicians. Improved diagnostic services, including the development and validation of point of care tests and testing strategies, and the development of diagnostic and management algorithms for patients presenting with febrile illness, are urgently needed in this setting, as in many others in the region \[[@pntd.0005508.ref019],[@pntd.0005508.ref054]\].

Summary {#sec015}
-------

The findings from this study strongly suggest that human brucellosis is being over-diagnosed in a mixed farming area of western Kenya. We expect that this is contributing to the over use of antibiotics, and has important economic impacts on affected patients. The FBAT used in government facilities throughout Kenya appears to have very poor diagnostic specificity and should be phased out. Further studies are needed to assess alternative diagnostic tests and testing strategies that can replace the FBAT in health facilities in the region. However, in the short term, and while awaiting the development of these alternatives, published recommendations and the results from this study suggest that the standard RBT, with antigen sourced from established sources with high standards of quality control, would provide a better alternative than the FBAT for the laboratory diagnosis of human brucellosis.
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